Index

Note: Page numbers of article titles are in boldface type.

A
Abdomen, radiation therapy in, late effects of, 1069
Abdominal pain
   in alcohol misuse, 998
   in inflammatory bowel disease, 973
Acamprosate, for alcohol misuse, 1006, 1029–1030
Acidosis, metabolic, in kidney disease, 947
Adalimumab
   for inflammatory bowel disease, 976, 978
   for sarcoidosis, 1137, 1146
Addiction, in homeless patients, 1028–1029
Albuminuria, in kidney disease, 944–945, 961
Albuterol, for asthma, 958, 961
Alcohol misuse, 989–1016
   conditions associated with, 995–999
   definitions of, 990
   economic impact of, 989
   epidemiology of, 990–994
   harms of, 994
   in liver disease, 916
   in solid organ transplant recipients, 1087
   screening for, 999–1001
   terminology of, 990
   treatment of, 1001–1007
   versus alcohol benefits, 994–995
   withdrawal in, 1005
Alcohol use disorder
   asking about, 993
   definition of, 990
Alcohol Use Disorders Identification Test (AUDIT), 999–1001
Alcoholic liver disease, 915
Alcoholics Anonymous, 1001–1003
Allergic rhinitis, asthma in, 955–956
5-Aminosalicylates, for inflammatory bowel disease, 976–977
Amiodarone
   avoidance of, in liver disease, 920
   for solid organ transplant recipients, 1093
Amnesia accumulation, in liver disease, 927–929
Amnesty International Report on torture, 1047
Anemia
   in alcohol misuse, 999
Anemia (continued)
  in kidney disease, 946
Angiotensin receptor blockers, for kidney disease, 943–944
Angiotensin-converting enzyme, in sarcoidosis, 1128
Angiotensin-converting enzyme inhibitors
  avoidance of, in liver disease, 920
  for kidney disease, 943–944
Ankylosing spondylitis, in inflammatory bowel disease, 972
Anticholinergic agents, for asthma, 959
Antidepressants, for solid organ transplant recipients, 1093
Antiepileptic drugs, avoidance of, in liver disease, 919
Antiretroviral therapy, for HIV infection
  adverse effects of, 1113
  goals of, 1106–1111
  in homeless patients, 1023–1024
  regimens of, 1113
  strategies for, 1111–1115
Anxiety disorders
  in alcohol misuse, 997
  in refugees, 1045–1048
Aphthous ulcers, in inflammatory bowel disease, 971–972
Apremilast, for sarcoidosis, 1146
Arrhythmias, in sarcoidosis, 1133
Arthritis, in inflammatory bowel disease, 971–972
Ascites, 922–924
Aspergillosis
  in sarcoidosis, 1132
  in solid organ transplant recipients, 1097
Aspirin, avoidance of, in asthma, 958
Asthma, 953–967
  classification of, 954
  complications of, 961–963
  diagnosis of, 955–957
  epidemiology of, 953
  exacerbations of, 960–961
  extrinsic, 954
  intrinsic, 954
  referral in, 961
  risk factors for, 954–955
  sarcoidosis with, 1130
  treatment of, 957–960
Asylees. See Refugees.
Atopy, asthma in, 955–956
AUDIT (Alcohol Use Disorders Identification Test), 999–1001
Azathioprine
  for inflammatory bowel disease, 976–977
  for sarcoidosis, 1145–1146
  for solid organ transplant recipients, 1091–1092
Azoles
  avoidance of, in liver disease, 919
  for solid organ transplant recipients, 1093
Balsalazide, for inflammatory bowel disease, 976–977
Bedbug infestations, in homeless patients, 1025–1026
Benzodiazepines
  for alcohol withdrawal, 1005
  for asthma, 958
Beta blockers, avoidance of, in liver disease, 920
Beta₂-agonists, for asthma, 958–960
Biomarkers, for alcohol, 1001
Biopsy
  in sarcoidosis, 1127, 1133
  in solid organ transplant recipients, 1079
  kidney, 942
  liver, 922
Bisexual persons, homeless, 1033–1034
Blastomycosis, in solid organ transplant recipients, 1096
Blindness, in sarcoidosis, 1138–1139
Bone density, evaluation of, in solid organ transplant recipients, 1087
Bone disease
  in kidney disease, 947
  in liver disease, 916–917
  in sarcoidosis, 1143
Brain
  radiation therapy on, late effects of, 1068–1069
  sarcoidosis of, 1126, 1135–1137
Brief Intervention, for alcohol misuse, 1003–1004
Bronchodilators, for asthma, 958–961
Budesonide
  for asthma, 958–959
  for inflammatory bowel disease, 976–977
  for sarcoidosis, 1130–1131
Bupropion, avoidance of, in liver disease, 919

C
Cachexia, in asthma, 961–962
CAGE questionnaire, for alcohol misuse, 1000
Calcification, in kidney disease, 947
Calcineurin inhibitors, for solid organ transplant recipients, 1089
Calcium, metabolism of, in kidney disease, 947
Calcium channel blockers
  avoidance of, in liver disease, 920
  for solid organ transplant recipients, 1093
Cancer
  cervical, 980–981
  colorectal, 981, 1086
  in HIV infection, 1108–1109
  in homeless patients, 1032
  in solid organ transplant recipients, 1086–1087, 1099–1100
  prostate, 1086
Cancer (continued)
  skin. See Skin cancer.
  survivors of. See Childhood cancer survivors.
Carbohydrate deficient transferrin, as alcohol biomarker, 1001
Cardiovascular disease
  in alcohol misuse, 994
  in childhood cancer survivors, 1064
  in HIV infection, 1108–1109, 1111–1115
  in homeless patients, 1022
  in kidney disease, 945
  in sarcoidosis, 1126, 1133–1135
  in solid organ transplant recipients, 1082–1083
Carvedilol, for varices, 927
Certolizumab pegol, for inflammatory bowel disease, 976, 978
Cervical cancer, screening for
  in inflammatory bowel disease, 980–981
  in solid organ transplant recipients, 1086
Chemotherapy, late effects of, 1067
Chest, radiation therapy on, late effects of, 1068
Chest pain, in sarcoidosis, 1133
Chest radiography
  for asthma, 956
  for sarcoidosis, 1126, 1129–1132
Childhood cancer survivors, 1059–1073
  history of, 1060
  late effects of, 1063–1070
  preventive care for, 1070–1071
  primary cancer recurrence in, 1061–1063
  statistics of, 1059–1060
  subsequent cancers in, 1061–1063
  treatment of, goals of, 1060
Children, homeless, 1032–1033
Children's Oncology Group Long-Term Follow-Up Guidelines, 1063
Child-Turcotte-Pugh score, 917–918, 929
Chronic illness
  alcohol misuse, 989–1016, 1087
  asthma, 953–967, 1130
  HIV infection, 1023–1024, 1105–1122
  in adult refugees, 1039–1058
  in childhood cancer survivors, 1058–1073
  in homeless patients, 1017–1138
  inflammatory bowel disease, 969–987
  kidney disease. See Kidney disease.
  liver disease. See Liver disease.
  sarcoidosis, 1123–1148
  solid organ transplantation, 1075–1103
Chronic obstructive pulmonary disease
  complications of, 961–963
  diagnosis of, 956
  in homeless patients, 1022
  treatment of, 957–958
Cigarette smoking. See Tobacco use.

Cirrhosis, 914
- complications for, 922–929
- in alcohol misuse, 998
- management goals for, 914–920
- monitoring of, 920–922
- palliative and end-of-life care in, 930
- prognosis for, 929
- transplantation for, 929

Clostridium difficile
- in solid organ transplant recipients, 1098–1099
- versus inflammatory bowel disease, 973

Coccidioidomycosis, in solid organ transplant recipients, 1096

Colitis, ulcerative. See Inflammatory bowel disease.

Colorectal cancer, screening for
- in inflammatory bowel disease, 981
- in solid organ transplant recipients, 1086

Communication
- with homeless patients, 1018–1019
- with refugees, 1041–1042

Computed tomography, for sarcoidosis, 1126

Consultation, with transplant specialists, 1083

Contraception, for solid organ transplant recipients, 1088

COPD. See Chronic obstructive pulmonary disease.

Corticosteroids
- for asthma, 958–959, 961
- for inflammatory bowel disease, 976–977
- for sarcoidosis, 1130–1131, 1140–1141, 1144–1146
- for solid organ transplant recipients, 1091–1092

Cough, in asthma, 955–956

Counseling, for alcohol misuse, 1002–1003

Creatinine levels, in kidney disease, 935–936, 940–941

Crohn disease. See Inflammatory bowel disease.

Cryptosporidiosis, in solid organ transplant recipients, 1099

Cyclophosphamide, for sarcoidosis, 1146

Cyclosporine, for solid organ transplant recipients, 1089–1090

Cytomegalovirus infections, in solid organ transplant recipients, 1095, 1099

D

Danger, to homeless patients, 1027–1028

Darier-Roussy sarcoidosis, 1140

Delirium tremens, 1005

Dental disorders, in childhood cancer survivors, 1066

Depression
- in alcohol misuse, 997
- in homeless patients, 1026–1027
- in inflammatory bowel disease, 982
- in refugees, 1045
- in sarcoidosis, 1143, 1145
- in solid organ transplant recipients, 1088
Dermatologic diseases, in childhood cancer survivors, 1065
Diabetes mellitus
  in HIV infection, 1115
  in homeless patients, 1021
  in refugees, 1049–1051
  in solid organ transplant recipients, 1080
  kidney dysfunction in, 939, 944–945
Dialysis, for kidney disease, 946–947
Diarrhea, in solid organ transplant recipients, 1098–1099
Diet and nutrition
  for hepatic encephalopathy, 929
  for homeless patients, 1021
  for inflammatory bowel disease, 982–983
  for liver disease, 915–916
  for refugees, 1049
  in alcohol misuse, 999
Discrimination, against homeless patient, 1018
Disulfiram, for alcohol misuse, 1003–1004, 1006, 1029–1030
Domestic medical evaluation, of refugees, 1042–1044
Drugs
  adjustments of, in kidney disease, 939–940
  for refugees, miscommunication about, 1049–1051
  for solid organ transplant recipients, 1078–1079, 1088–1093
  management of, in liver disease, 918–920
Duloxetine, avoidance of, in liver disease, 919
Dyspnea
  in asthma, 955–956
  in sarcoidosis, 1132

E
Ear, disorders of, in childhood cancer survivors, 1066
Elderly persons, homeless, 1033
Employment situation, for childhood cancer survivors, 1070
Encephalopathy
  hepatic, 927–929
  Wernicke, 999
Endocrine disorders, in childhood cancer survivors, 1065
End-of-life care. See Palliative and end-of-life care.
Enterococcus infections, in solid organ transplant recipients, 1098
Epidemiology of Diabetes and Ramadan study, 1050
Episcleritis, in inflammatory bowel disease, 971–972
Erythema nodosum
  in inflammatory bowel disease, 971–972
  in sarcoidosis, 1139–1140
Erythrocytosis, in solid organ transplant recipients, 1082
Escherichia coli infections, in solid organ transplant recipients, 1098
Esophageal varices, 924–927
Ethyl glucuronide, as alcohol biomarker, 1001, 1007
Ethyl sulfate, as alcohol biomarker, 1001
Everolimus, for solid organ transplant recipients, 1091
Exercise, for liver disease, 915–916
Eye disorders
  in childhood cancer survivors, 1066
  in sarcoidosis, 1126, 1138–1139

F
Facial nerve palsy, in sarcoidosis, 1135
Fasting, in refugee population, 1050, 1052
Fatigue, in sarcoidosis, 1140–1141
Fistulization, in Crohn disease, 971
Flea infestations, in homeless patients, 1025–1026
Fluticasone, for asthma, 958–959
Formoterol, for asthma, 959
Fractures
  in alcohol misuse, 999
  in sarcoidosis, 1138
Fungal infections, in solid organ transplant recipients, 1096

G
Gamma-glutamyltransferase, as alcohol biomarker, 1001
Gastrointestinal disorders, in childhood cancer survivors, 1064
Gay persons, homeless, 1033–1034
Gender differences, in asthma, 954–955
Genetic factors, in asthma, 955
Glaucoma, in sarcoidosis, 1138–1139
Glomerular filtration rate, in kidney disease, 936–937, 940–941, 944
Granulomas, in sarcoidosis. See Sarcoidosis.

H
Harvard Trauma Questionnaire, 1045–1046
Head, radiation therapy on, late effects of, 1068–1069
Health insurance, for refugees, 1040–1041
Heart disease. See Cardiovascular disease.
Heart failure, in homeless patients, 1022
Heart transplantation. See Solid organ transplant recipients.
Hepatic encephalopathy, 927–929
Hepatitis B and/or hepatitis C
  cirrhosis and complications management in, 922–929
  in alcohol misuse, 998
  in HIV infection, 1107–1108
  in homeless patients, 1022–1023
  in refugees, 1044
  in solid organ transplant recipients, 1095
  management goals for, 914–920
  monitoring of, 920–922
  palliative and end-of-life care in, 930
  prognosis for, 929
  transplantation for, 929
Hepatocellular carcinoma, 922, 929, 1044
Herpes zoster vaccinations, contraindicated for solid organ transplant recipients, 1084–1085
Histoplasmosis, in solid organ transplant recipients, 1096
History, of solid organ transplant recipients, 1077–1081
HIV infection. See Human immunodeficiency virus infection.
Homeless patients, 1017–1038
  clinic visit by, 1018–1020
  palliative care for, 1034
  preventive care for, 1030–1032
  respite facilities for, 1034
  specialists focusing on, 1034
  specific populations of, 1032–1034
  specific problems of, 1021–1032
Hopkins Symptom Checklist, 1045–1046
Hospice care, for liver disease, 930
Housing, for homeless people, 1034
Human immunodeficiency virus infection, 1105–1122
  comorbidities with, 1107–1110
  detection of, 1106
  in homeless patients, 1023–1024
  management goals for, 1106–1111
  monitoring of, 1116–1118
  nonpharmacologic strategies for, 1111–1116
  opportunistic infections in, 1111–1115
  pharmacologic strategies for, 1111–1115
  preventive care for, 1115–1116
  recurrence of, 1116, 1118
  screening for, 1106, 1115–1116
Human papillomavirus vaccination, for solid organ transplant recipients, 1084–1085
Hydrocortisone, for inflammatory bowel disease, 976–977
Hydroxychloroquine, for sarcoidosis, 1140, 1145–1146
Hyperammonemia, in liver disease, 927–929
Hypercalcemia, in sarcoidosis, 1133, 1138
Hyperglycemia, in homeless patients, 1021
Hyperkalemia, in kidney disease, 947
Hyperlipidemia, in solid organ transplant recipients, 1080
Hyperparathyroidism, in kidney disease, 947
Hypertension
  in alcohol misuse, 997–998
  in homeless patients, 1021–1022
  in refugees, 1049
  in solid organ transplant recipients, 1080
Hyperuricemia, in solid organ transplant recipients, 1080
Hypothalamic-pituitary axis dysfunction, in sarcoidosis, 1135
Hypoxemia, for asthma, 962–963

Immigrants, refugee. See Refugees.
Immune system disorders, in childhood cancer survivors, 1066
Immunizations. See Vaccinations.

Immunosuppressive agents, for solid organ transplant recipients, 1089–1093

Infections
  asthma in, 955
  in homeless patients, 1024–1026
  in kidney disease, 945–946
  in solid organ transplant recipients, 1077
  inadmissible, in refugees, 1042

Inflammatory bowel disease, 969–987
  clinical presentation of, 970–973
  demographics of, 970
  differential diagnosis of, 973–975
  pathology of, 970–973
  preventive health maintenance in, 978–983
  risk factors for, 970
  severity indices of, 975–976
  treatment of, 975–978

Infliximab
  for inflammatory bowel disease, 976, 978
  for sarcoidosis, 1137–1138, 1146

Influenza, in homeless patients, 1024

Influenza vaccine, for solid organ transplant recipients, 1084–1085

Inhaler therapy, for asthma, 958–960

Injuries, in homeless patients, 1027–1028

Insomnia, in alcohol misuse, 995–996

Insulin, for homeless patients, 1021

Interpreters, for refugees, 1041–1042

Interstitial nephritis, in sarcoidosis, 1138

Intestine transplantation. See Solid organ transplant recipients.

Ipratropium, for asthma, 959

Iron supplements, for inflammatory bowel disease, 982–983

K

Kidney disease, 935–952
  complications of, 946–947
  epidemiology of, 936–937
  evaluation of, 938–940
  in childhood cancer survivors, 1064
  in HIV infection, 1108, 1112, 1114
  in sarcoidosis, 1126, 1137–1138
  in solid organ transplant recipients, 1080
  laboratory studies for, 940–942
  mortality in, 937–938
  natural history of, 937–938
  progression of, 938
  referral in, 947–948
  screening for, 939
  stages of, 936
  treatment of, 942–946

Kidney transplantation. See Solid organ transplant recipients.
Koebner phenomenon, 1140
Korsakoff syndrome, 999

L
Lactulose, for hepatic encephalopathy, 928
Language barriers, for refugees, 1041–1042
Leflunomide, for sarcoidosis, 1146
Lesbian, gay, bisexual, and transgender persons, homeless, 1033–1034
Leukotriene receptor antagonists, for asthma, 959–960
Lice, in homeless patients, 1024–1025
Lifestyle changes
   for asthma, 957–958
   for homeless patients, 1021
   for liver disease, 915–916
Liver disease, 913–933. See also Hepatitis B and/or hepatitis C.
   alcoholic, 998
   cirrhosis and complications management in, 922–929
   in childhood cancer survivors, 1064
   in homeless patients, 1022–1023
   in sarcoidosis, 1126, 1144
   in solid organ transplant recipients, 1082
   management goals for, 914–920
   monitoring of, 920–922
   palliative and end-of-life care in, 930
   prognosis for, 929
   transplantation for, 930
Liver transplantation. See Solid organ transplant recipients.
Löfgren syndrome, 1141–1142
Lung
   cancer of, screening for, 1086
   sarcoidosis of, 1129–1132
   transplantation of. See Solid organ transplant recipients.
Lupus pernio, 1139–1140, 1144
Lymphadenopathy, in sarcoidosis, 1143

M
Macrolides
   avoidance of, in liver disease, 919
   for solid organ transplant recipients, 1093
Magnetic resonance imaging, for neurosarcoidosis, 1137
Malnutrition, in alcohol misuse, 999
Mean corpuscular volume, as alcohol biomarker, 1001
Medical respite care, for homeless people, 1034
Medications. See Drugs.
Mental health disorders
   in homeless patients, 1026–1027
   in refugees, 1044–1048
   in solid organ transplant recipients, 1088
6-Mercaptopurine, for inflammatory bowel disease, 976–977
Metabolic acidosis, in kidney disease, 947
Metabolic disorders
  in childhood cancer survivors, 1065
  in solid organ transplant recipients, 1088
Metformin
  avoidance of, in liver disease, 920
  in kidney disease, 944–945
Methadone maintenance programs, 1029
Methotrexate
  for inflammatory bowel disease, 976, 978
  for sarcoidosis, 1144–1146
Methylprednisolone
  for inflammatory bowel disease, 976–977
  for sarcoidosis, 1137
Mineral and bone disorders, in kidney disease, 947
Model for End-Stage Liver Disease (MELD) score, 917–918, 929
Mometasone, for asthma, 958–959
Monoamine oxidase inhibitors, for solid organ transplant recipients, 1093
Montelukast, for asthma, 959–960
Mortality
  in HIV infection, 1107–1109
  in kidney disease, 937–938
Motor vehicle accidents, homeless patients in, 1027–1028
Musculoskeletal disorders, in childhood cancer survivors, 1065
Mutual self-help groups, for alcohol misuse, 1003–1005
Mycobacterium avium complex infections, prevention of, in HIV infection, 1114
Mycobacterium tuberculosis, screening for, in inflammatory bowel disease, 980, 983
Mycophenolate
  for sarcoidosis, 1146
  for solid organ transplant recipients, 1089, 1091–1092
Myocardial infarction, in homeless patients, 1022

N
Nadolol, for varices, 927
Naltrexone, for alcohol misuse, 1003–1006, 1029–1030
Nasal disorders, in sarcoidosis, 1142
Neck, radiation therapy on, late effects of, 1068
Neurologic disorders
  in childhood cancer survivors, 1066
  in HIV infection, 1108
  in sarcoidosis, 1126, 1135–1137
Nonalcoholic fatty liver disease, 915
Nonalcoholic steatohepatitis, 915
Nonsteroidal anti-inflammatory drugs, avoidance of
  in asthma, 958
  in liver disease, 918–919
Norovirus infections, in solid organ transplant recipients, 1099
Nosocomial infections, in solid organ transplant recipients, 1094–1095
Nutrition. See Diet and nutrition.
O

Obesity, asthma in, 955
Obstructive sleep apnea, in homeless patients, 1022
Occupational exposure, asthma in, 954
Ocular disorders, in sarcoidosis, 1126, 1138–1139
Older adults, homeless, 1033
Olsalazine, for inflammatory bowel disease, 976–977
Opioids, avoidance of, in liver disease, 919–920
Opportunistic infections
  in HIV infection, 1111–1115
  in sarcoidosis, 1131–1132
Ophthalmologic screening, in inflammatory bowel disease, 981–982
Osteodystrophy, renal, 947
Osteopenia
  in liver disease, 916–917
  in sarcoidosis, 1143
Osteoporosis
  in alcohol misuse, 998–999
  in corticosteroid therapy, 959, 962
  in HIV infection, 1112
  in inflammatory bowel disease, 972, 980
  in liver disease, 916–917
  in sarcoidosis, 1138
  in solid organ transplant recipients, 1087
  treatment of, 962
Overseas evaluation, of refugees, 1042
Oxygen therapy, for asthma, 962–963

P

Pain
  in alcohol misuse, 996–997
  in homeless patients, 1029–1030
  in refugees, 1048
Palliative and end-of-life care
  for homeless patients, 1034
  for liver disease, 930
Pancreas transplantation. See Solid organ transplant recipients.
Pancreatitis, in alcohol misuse, 998
Paracentesis, for ascites, 923–924
Parasitic infections
  in homeless patients, 1024–1026
  in refugees, 1042–1043
Pathways to Wellness program, 1046
Pelvis, radiation therapy in, late effects of, 1069
Pentoxifylline, for sarcoidosis, 1146
Peripheral neuropathy, in sarcoidosis, 1135–1136
Permethrin, for parasitic infections, 1025–1026
Phosphatidyl ethanol, as alcohol biomarker, 1001
Pigmentation disorders, in sarcoidosis, 1139–1140
Pneumococcal vaccinations
  for homeless patients, 1030–1031
  for solid organ transplant recipients, 1084–1085
  in kidney disease, 946
Pneumocystis pneumonia, prevention of, in HIV infection, 1114
Pneumonia, in solid organ transplant recipients, 1096–1097
Posttransplant lymphoproliferative disorder, 1099–1100
Posttraumatic stress disorder
  in homeless patients, 1028
  in refugees, 1045
Prednisone
  for asthma, 959
  for inflammatory bowel disease, 976–977
  for sarcoidosis, 1133, 1137, 1144–1145
  for solid organ transplant recipients, 1091–1092
Pregnancy, in solid organ transplant recipients, 1088
Preventive care
  for childhood cancer survivors, 1070–1071
  for HIV infection, 1114–1116
  for homeless patients, 1030–1032
  for inflammatory bowel disease, 978–983
  for solid organ transplant recipients, 1083–1088
Primary sclerosing cholangitis, in inflammatory bowel disease, 972
Propranolol, for varices, 927
Prostate cancer, screening for, in solid organ transplant recipients, 1086
Proteinuria, in kidney disease, 940–942
Pseudomonas infections, in solid organ transplant recipients, 1098
Psychiatric disorders
  in alcohol misuse, 997
  in solid organ transplant recipients, 1093
Psychosocial issues, in childhood cancer survivors, 1070
Pulmonary disease, in childhood cancer survivors, 1064
Pulmonary function testing, for sarcoidosis, 1130–1131
Pyoderma gangrenosum, in inflammatory bowel disease, 972

Q
Quantiferon test, for sarcoidosis, 1125
Quarantinable conditions, in refugees, 1042

R
Rackemann classification, of asthma, 954
Radiation therapy, late effects of, 1067–1069
Refugee Health Screener, 1046
Refugees, 1039–1058
  chronic diseases in, 1048–1052
  domestic medical evaluation of, 1042–1044
  language barriers with, 1041–1042
  legal status of, 1040–1041
  mental health issues in, 1044–1048
Refugees (continued)
  origin of, 1039–1040
  overseas evaluation of, 1042
Rejection, in solid organ transplant recipients, 1077
Renal osteodystrophy, 947
Reproductive system disorders, in childhood cancer survivors, 1065
Respiratory disorders
  in homeless patients, 1022
  in sarcoidosis, 1129–1132
Rifamixin, for hepatic encephalopathy, 929

S
Sacroiliitis, in inflammatory bowel disease, 972
Safety, of homeless patients, 1027–1028
Salmeterol, for asthma, 959
Sarcoidosis, 1123–1148
  asymptomatic, 1128
  bone disease in, 1143
  cardiac involvement in, 1126, 1133–1135
  clinical outcome of, 1125
  cutaneous involvement in, 1126, 1139–1140
  evaluation, 1124–1128
  extrapulmonary, 1125–1126
  fatigue in, 1140–1141
  follow-up in, 1128–1129
  kidney disease in, 1126, 1137–1138
  laboratory tests for, 1127–1128
  liver involvement in, 1126
  natural history of, 1124
  neurologic involvement in, 1126, 1135–1137
  nongranulomatous (Löfgren syndrome), 1141–1142
  of respiratory system, 1129–1132
  risk factors for, 1124
  sinonasal, 1126, 1142–1143
  treatment of, 1143–1147
Scabies, in homeless patients, 1024–1025
Schistosomiasis, in refugees, 1043–1044
Screening, for infections in liver disease, 916
Selective serotonin reuptake inhibitors
  for homeless patients, 1029
  for solid organ transplant recipients, 1093
Sexual behavior, in HIV infection, 1115–1116
Sinonasal sarcoidosis, 1126, 1142–1143
Sirolimus, for solid organ transplant recipients, 1091–1092
Skin cancer
  in childhood cancer survivors, 1062
  in solid organ transplant recipients, 1100
  screening for
    in inflammatory bowel disease, 981
    in solid organ transplant recipients, 1087
Skin disorders
  in childhood cancer survivors, 1065
  in sarcoidosis, 1126, 1139–1140
Skip lesions, in Crohn disease, 971
Small-fiber neuropathy, in sarcoidosis, 1126, 1135–1137
Smoking. See Tobacco use.
Social functioning, in childhood cancer survivors, 1070
Solid organ transplant recipients, 1075–1103
  assessment of, 1076–1081
  follow-up visits for, 1081–1083
  infectious complications in, 1087, 1094–1098
  malignancy risk in, 1099–1100
  medication interactions and side effects in, 1088–1093
  organ-specific issues in, 1082–1083
  preventive health measures for, 1083–1088
  statistics for, 1075–1076
  survival rate of, 1076
  systemic illnesses leading to, 1080
  transplant locations in, 1081
Somatization, in refugees, 1048
Specialization, in care of homeless people, 1034
Specialty behavioral addictions treatment, 1003–1005
Spider telangiectasia, 1020
Spinal cord, sarcoidosis of, 1135–1136
Spine, radiation therapy in, late effects of, 1069
Spirometry, for asthma, 956
Spontaneous bacterial peritonitis, in liver disease, 924
Statins
  for HIV infection, 1116
  for solid organ transplant recipients, 1093
  kidney disease and, 945
Steatosis, in alcohol misuse, 998
Stones, kidney, in sarcoidosis, 1138
Stress, in refugees, 1044–1048
Strongyloides infections, in refugees, 1043
Substance abuse. See also Alcohol misuse.
  in homeless patients, 1028
  in solid organ transplant recipients, 1087
Suicide, in refugees, 1045
Sulfasalazine, for inflammatory bowel disease, 976–977
Sun protection, in inflammatory bowel disease, 981
Surgery, assessment for, in liver disease, 917–918

T
Tacrolimus, for solid organ transplant recipients, 1089–1090
Teens, homeless, 1033
Tetracyclines, avoidance of, in liver disease, 919
Theophylline, for asthma, 960
Tinea pedis, 1020
Tiotropium, for asthma, 959
Tobacco use
- asthma and, 954
- in alcohol misuse, 997
- in HIV infection, 1115
- in homeless patients, 1021
- in inflammatory bowel disease, 982
- in liver disease, 916
- in solid organ transplant recipients, 1087

Torture, survivors of, 1046–1048

Toxoplasmosis, prevention of, in HIV infection, 1114

Transgender persons, homeless, 1033–1034

Transjugular intrahepatic portosystemic shunt, for ascites, 924

Transplantation. See Solid organ transplant recipients.

Trauma, in homeless patients, 1027–1028

Traveling, with inflammatory bowel disease, 983

Trimethoprim sulfamethoxazole, for solid organ transplant recipients, 1095–1096

Tuberculin skin test, 980, 983

Tuberculosis
- in HIV infection, 1114
- in homeless patients, 1024
- in refugees, 1042–1043

U

Ulcerative colitis. See Inflammatory bowel disease.

Urinary tract disorders, in childhood cancer survivors, 1064

Urinary tract infections, in solid organ transplant recipients, 1096–1097

Uveitis
- in inflammatory bowel disease, 972
- in sarcoidosis, 1139

V

Vaccinations
- for homeless patients, 1030
- for refugees, 1042
- for solid organ transplant recipients, 1083–1085
- in HIV infection, 1115, 1117
- in inflammatory bowel disease, 978–980, 983
- in kidney disease, 946
- in liver disease, 916

Varicella vaccinations, contraindicated for solid organ transplant recipients, 1084–1085

Varices, 924–927

Venous insufficiency, 1020

Venous thromboembolism, in inflammatory bowel disease, 973

Veterans, homeless, 1033

Violence, against homeless patients, 1027–1028

Vitamin supplements, for inflammatory bowel disease, 982–983
W
Weight loss
   in asthma, 961–962
   in sarcoidosis, 1143
Weight management, for liver disease, 915–916
Wernicke encephalopathy, 999
Wheezing, in asthma, 955–956
White blood cell count, for asthma, 956–957
Wilson disease, 915–916
Withdrawal, in alcohol misuse, 1005
Women, homeless, 1032–1033

Z
Zafirlukast, for asthma, 959–960